Brief: Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension
23/09/2026 22:07
BRIEF-Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension Sept 24 (Reuters) - Gossamer Bio, Inc. GOSS.O:
GOSSAMER BIO SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR SERALUTINIB FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
GOSSAMER BIO, - FDA TO DETERMINE NDA ACCEPTANCE FOR FILING LATER THIS YEAR
Source text: ID:nBwbB6X6Ca
Further company coverage: GOSS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gossamer Bio
See all newsBrief: Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Gossamer Bio - Board Approves Amendment And Restatement Of Bylaws Effective Sept 3, 2026 - SEC Filing